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Absence of inhibition of C'I esterase from plasma of persons with hereditary angio- 
neurotic edema (1)  has been ascribed to at least two inherited  abnormalities  of bio- 
synthesis of a  specific  alpha globulin which inhibits  C'I esterase  (2).  These defects 
have permitted studies of the activation of the first component of complement (C'I) 
and of the action of C'I esterase in unfraefionated serum and plasma. In the absence 
of serum  inhibition  of C'1 esterase,  C'I  tends  to be converted to  Cq  esterase  (3). 
This tendency to spontaneous activation of C'I esterase in plasma from persons with 
hereditary  angioneurotic  edema  is  notably  increased  during  the  bouts  of  swelling 
which these individuals  sustain  (3,  4).  Such variations in activation of C'I esterase 
cannot be due merely to the lack of normal serum inhibition,  for this  deficiency is 
lifelong,  and the bouts of edema and associated enhanced activation of C'I esterase 
are sporadic. 
In experiments  designed to measure the in vitro development of C'I esterase ac- 
tivity in plasma from persons with hereditary angioneurotic edema, esterolytie activ- 
ity attributable to this enzyme was increased when glass rather than silicone-coated 
vessels were used. This suggested that one or more enzymes reactive to contact with 
foreign surfaces, such as glass,  and effective in the generation of clot-promoting ac- 
tivity might influence the action of C'I. Lister (5)  observed that contact with glass 
surfaces seemed  to initiate  the dotting of blood,  a  phenomenon also recognized by 
Bordet and Gengou (6). Ratnoff and his associates (7, 8) have provided firm evidence 
that  a  specific  plasma protein,  now called Hageman factor (9),  is  required  for the 
generation  of dot-promoting activity which occurs when plasma comes in contact 
with a  surface such as glass.  Hageman factor is markedly deficient in the plasma of 
persons with Hageman trait. 
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When  partially purified  preparations of  Hageman  factor  were  activated, 
in the experiments to be described, besides acquiring clot-promoting activity, 
they developed the capacity to enhance the generation of C'1 esterase in plasma, 
prepared with silicone-coated  equipment, obtained from persons with hereditary 
angioneurotic edema in remission. Purified serum inhibitor of Crl esterase func- 
tionally obscured the activation of CI1 in this plasma. Certain other inhibitors 
which do not impair the action of CI1 esterase blocked the generation of this 
enzyme in the plasma of persons with hereditary angioneurotic edema treated 
with activated Hageman factor. 
Materials  and  Methods 
Plasma samples from normal persons and persons with hereditary  angioneurotic edema, 
inherited defciencies of plasma thromboplasfin antecedent (PTA or factor  XI), or Hageman 
factor  (factor XII) were separated from blood drawn with  silicone-coated syringes (SC-87, 
G-E Dri-Film) into Na~I-I2EDTA  already dissolved in 0.13 ~ sodium citrate, pH 5.2, to give 
a final Na~I2EDTA concentration of 6 X  10  -3 ~.1 Plasma  samples were rendered platelet- 
deficient by centrifugation at 20,000  g for 15 rain at 2°C in an International PR-2 centrifuge. 
The plasma at no time came in contact with glass, and samples were divided and stored at 
-20°C or -65°C in silicone-coated containers (Lusteroid Container Co., Inc., Maplewood, 
N.J.) until used. 
Partially purified Hageman  factor  was prepared  from  siliconed plasma  obtained  from 
normal persons, an individual with Hageman trait, and an individual with an inherited de- 
ficiency of PTA. The method of purification of Hageman factor was modified from that used 
by Ratnoff, Davie, and Mallet  (10) in that the capacitance of the carboxymethyl cellulose 
used was 0.6 meq of hydrogen ion per gram. These solutions of ttageman factor were stored 
in silicone-coated  Lusteroid containers at --65°C and used within i wk. The Hageman factor 
was dissolved in sodium phosphate buffer in a volume equal to that of the plasma from which 
they were derived. Thus, its concentration in experimental mixtures was less than in plasma. 
A preparation of Hageman factor representing a 2000-500(0fold purification with respect 
to starting plasma was used in some experiments employing "highly purified Hageman fac- 
tor." This Hageman factor, prepared as described by Ratnoff and Davie (11) and provided 
by Dr. O. D. Ratnoff, was largely in the form of an inactive precursor. It was dissolved in 
0.067 ~  sodium phosphate buffer (pH 7.4) at 10 times the concentrations desired in experi- 
mental mixtures. 
The amounts of Hageman factor (the inactive precursor) and activated ttageman faaor in 
the preparations used were measured by testing the ability of the solutions of Hageman fac- 
tor to shorten the clotting time of plasma obtained from an individual with an inherited de- 
ficiency of this factor. This plasma, from Mr. John Hageman, was also provided by Dr. O. D. 
Ratnoff. The shortening of the clotting time of this plasma in the presence of "cephalin"  (12) 
and calcium in silicone-coated test  tubes reflected the action of activated Hageman factor. 
The shortening of the clotting time induced by Hageman factor preparations in the presence 
of kaolin and a phospholipid (Gliddex-p, Glidden Paint Co., Chicago, Ill.) and calcium was 
a measure of both the activated Hageman factor and its precursor in the preparation. The 
methods used and preparation of the reagents have been described elsewhere (12-14). 
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Crude C'I esterase was prepared from serum of a  normal person and  serum of a  person 
with Hageman trait (severe inherited deficiency of Hageman factor). A euglobulin precipitate 
was prepared by mixing 1 volume of serum with 8 volumes of 0.02 ~r acetate buffer at a pH of 
5.5.  The precipitate was dissolved in a  volume of 0.067 ~  sodium phosphate buffer, pH 7.4, 
equal to ~0  that of starting serum. Mter dialysis for 48 hr against pH 7.4 sodium phosphate 
buffer at 4°C, these preparations of Ctl esterase were rendered active by incubation at 37°C 
for 30 min and tested for properties attributable to Ctl esterase. 
A preparation of human serum inhibitor of Cq esterase, representing at least a  2000-fold 
purification with respect to starting serum, was generously provided by Dr. Jack Pensky of 
Western Reserve University. 
F_llagic acid (4,4  t , 5,5  ~  , 6,6t-hexahydroxydiphenic acid 2,6,2 p  ,6t-dilactone)  was  obtained 
from K  and K  Laboratories, Inc., Plainview, N. Y. It was mixed with buffer to provide a 
concentration of  10  -3 M. Mter mechanical homogenization of this somewhat insoluble ma- 
terial, the mixture was centrifuged at 37,000 g for  15 rain in a  Servall RC-2 centrifuge to 
remove  any  remaining insoluble substance. The supematant  ellagic acid  solution, freshly 
prepared, was diluted in experimental procedures as noted. 
Trasylol (compound A-128, proteinase inactivator), a  kallikrein inhibitor,  was used in a 
concentration of 625 tmits/ml in incubation mixtures and diluted to 125 units/ml in titration 
mixtures.  Heparin  (The Upjohn Co.,  Kalamazoo,  Mich.),  in  a  concentration of  125  USP 
units/ml of incubation mixtures, was diluted to 25 USP units/ml in titration  mixtures. Ep- 
silon aminocaproic acid (Mann Research Laboratories, New  York,  N.Y.)  was dissolved in 
0.15 ~  sodium chloride in a concentration of 1.0 ~; it was  used in a concentration of 0.125 M 
in incubation mixtures and, in titration mixtures, diluted to 0.025 ~. Soybean trypsin inhibitor 
(5  X  crystallized, Nutritional Biochemicals Corp.,  Cleveland, Ohio) was used at a  concen- 
tration of 1.25 mg/ml in incubation mixtures and 0.250 mg/ml during titrations. 
N-acetyl-L-tyrosine ethyl ester monohydrate (A LTEE),  t prepared in the laboratories of The 
Department of Chemistry, Western Reserve University by Mr. Albert Arters, was dissolved 
in 2-methoxyethanol (Methyl Cellosolve, Matheson Co., Norwood, Ohio) in a  concentration 
of 1.6 a  for use as substrate in assays measuring C'I esterase activity; R4, a  serum reagent 
markedly deficient in the fourth component of complement (C~4) and used to titrate Ct4 in 
experimental mixtures,  was  prepared  by  treating normal serum  with hydrazine  (15,  16). 
Normal serum was heated to 56°C for 30 rain to provide a source of Cr4 free of Ctl and Ct2. 
To prepare sensitized erythrocytes for use in fitrating hemolytic complement, sheep erythro- 
cytes were washed 4 or more times in 10 times their volume of cold 0.15 ~  sodium chloride, 
and incubated with a  ~000  dilution of rabbit antiserum to sheep erythrocytes  (Baltimore 
Biological Laboratories, Baltimore, Md).  I 
Triethanolamine-buffered saline  containing  calcium,  magnesium,  and  gelatin  was  pre- 
pared according to the method of Kent et al. (17)  at a pH of 7.4 and ionic strength of 0.15, 
and was used in assays titrating hemolytic C~4 activity. Sodium phosphate buffer, at a pH of 
7.4 and ionic strength of 0.15, was used in assays measuring ALTEE hydrolysis. Barbital- 
saline buffer, pH 7.4 and ionic strength 0.15,  was used in coagulation studies and contained 
7.8 g of sodium chloride, 2.76 g of barbital, and 2.06 g of sodium barbital in 1 liter of distilled 
water. 
Continuous monitoring of ALTEE hydrolysis by plasma mixtures was carried out with a 
Radiometer pH meter (Radiometer, Copenhagen, Denmark, model PHM 27 with expanded 
scale), automatic titrator (model TTT 11), and a 2.5 ml syringe burette (ABU 19). To main- 
rain a  constant temperature of 37°C  and constant pH, jacketed electrode vessels connected 
to a  continuously circulating water bath at 37°C  were used with a  magnetic stirrer. Elec- 
trodes and vessels were coated with silicone (Stopcock Grease, Dow Coming Corp., Midland, 
Mich.).  Plasma samples of 0.5 ml each, and  1.875  ml of phosphate buffer were warmed to 414  ACTIVATION OF ctl  ESTERASE 
37°C for 10 rain in a titration vessel. The pH of this mixture was adjusted to 7.45-7.47, if not 
at this point, and 0.125 ml of 1.6 •  ALTEE rapidly injected via syringe and needle as a stop 
clock was started. Readings  of the volume of 0.05 N sodium hydroxide titrated to  maintain 
the pH of the mixture at 7.4 were taken at 2 rain intervals. If the pH of the enzyme-substrate 
mixture rose to 7.5 before esterolysis began, it was lowered to 7.45-7.47 with 0.1 N HC1. 
To test the effect of Hageman factor upon the generation of ALTEE esterase activity in 
hereditary angioneurotic  edema plasma samples obtained during remissions, 0.18 ml of the 
Hageman factor preparation in solution was mixed with 0.02 mi of 10- 8  ~t ellagic acid at room 
temperature. Ellagic acid in solution has been shown to activate Hageman factor (14). The 
ellagic acid-activated Hageman factor was then mixed with 0.5 ml of the plasma to be tested 
for activation of its Ctl esterase. These mixtures were incubated in silicone-coated Lusteroid 
test tubes at 37°C for the time intervals noted and 0.5 ml of each was then used to measure 
esterolysis  in  the  incubation  and  titration  mixtures  described.  Hereditary angioneurotic 
edema plasma was incubated with buffer,  ellagic acid,  or ellagic acid-activated Hageman 
factor  and  the  differences  in  ALTEE-esterolytic activity generated were  then  measured 
during continuous acidimetric titrations. Esterolysis generated was also compared with that 
formed in mixtures of hereditary angioneurotic  edema plasma and "unactivated" HHageman 
factor and "activated" Hageman factor prepared from plasma deficient in this factor. 
The ability of preparations of Hageman factor and of mixtures  of Hageman factor and 
hereditary angioneurotic  edema plasma to inactivate the fourth component  of complement 
(CP4) was tested by the method of Haines and Lepow (18). 
RESULTS 
Effect  of Activated  Hageman  Factor on the Generation of ALTEE Esterolytic 
Activity in Hereditary Angioneurotic  Edema Plasma.-Freshly prepared plasma 
from  normal  individuals or persons  with  hereditary  angioneurotic  edema  in 
remission  did not hydrolyze N-acetyl-L-tyrosine ethyl ester  (ALTEE).  While 
normal plasma did not  digest ALTEE  even  after prolonged incubation with 
10  -4 ~r ellagic acid, plasma from a person with hereditary angioneurotic edema 
in  remission  developed  this  esterolytic  activity  during  incubation  with 
10  -4 ~  ellagic acid. Usually, both the rate at which ALTEE-hydrolytic activ- 
ity appeared and the quantity of ester hydrolyzed were increased when plasma 
obtained during remission was incubated with ellagic acid instead of with buffer. 
Fig. 1 illustrates the effect of prolonged incubation of ellagic acid with heredi- 
tary angioneurotic edema plasma at 4°C. 
Ellagic acid converts Hageman factor to an active clot-promoting substance 
(14).  To determine whether  the ALTEE  esterase activity in hereditary angio- 
neurotic edema plasma might have resulted from the activation of the Hageman 
factor in this plasma, a  highly purified preparation of human Hageman factor 
was treated with 10  -4 M ellagic acid and then incubated at 37°C with hereditary 
angioneurotic edema plasma which had not developed ALTEE-esterase activ- 
ity.  The  highly purified activated Hageman  factor induced ALTEE-esterase 
activity in the plasma, and both the rate of generation of esterolysis and amount 
of ester digested were increased in relative proportion to the quantity of acti- 
vated Hageman  factor which  was originally incubated with  the plasma  (Fig. 
2).  In  this  experiment,  very  little esterolytic activity was  generated  during V.  H.  DONALDSON  415 
incubation of the plasma with buffer or with ellagic acid alone for 1 hr at 37°C 
prior to titration  of its effect upon ALTEE. The quantity of Hageman factor 
used  in  this  experiment  far  exceeded  the  concentrations  which  might  occur 
in plasma. 
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FIG. 1. Samples of plasma from a person with hereditary angioneurotic edema were mixed 
with ellagic acid or buffer and stored in silicone-coated vessels at 4°C for 48 hr. Then,  each 
sample was tested for its ability to hydrolyze ALTEE during constant automatic  titration  at 
37°C in a Radiometer pH-stat.  Open circles designate the rate of ALTEE hydrolysis by the 
sample stored with  ellagic acid; closed circles describe the rate of hydrolysis by the same 
sample stored with buffer. 
To determine if the enhanced formation of ALTEE-esterase activity in mix- 
tures of activated Hageman factor and hereditary angioneurotic edema plasma 
was due to the activated Hageman factor rather than to a contaminating sub- 
stance, partially purified Hageman factor was prepared from the plasma of Mr. 
Hageman, severely deficient in this plasma protein (8, 9). The preparation was 
less pure than the material used in the previous experiments,  but was used in 
concentrations approximating  those more likely to occur in plasma.  Hageman 416  ACTIVATION 0~"  Ctl  ESTERASE 
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FzG. 2.  Curves in  the  upper  panel  describe rates  of ALTEE hydrolysis by hereditary 
angioneurotic edema (HANE) plasma which had been treated with varying concentrations of 
ellagic acid-activated highly purified Hageman factor (HF), and lack of activity in eUagic acid 
activated Hageman factor alone.  Curves in the lower panel represent rates of ALTEE hy- 
drolysis by the same plasma treated with buffer or eUagic acid without added Hageman factor. 
Before assay, 0.5 ml samples of the plasma had been incubated with 0.05 ml of the additive 
for 2 hr at 37°C in silicone-coated vessels.  In the assays,  0.5 ml of these incubation mixtures 
were tested for ALTEE hydrolytic activity. 
factor prepared from normal plasma and plasma deficient  in plasma thrombo- 
plastin antecedent was also tested. None of the preparations of Hageman factor 
hydrolyzed ALTEE by themselves even after activation with ellagic acid. Nor 
could an increase in the generation of ALTEE-esterase in the mixture be dem- 
onstrated  after  incubation  of mixtures of ellagic acid-activated  "Hageman- 
deficient" Hageman factor with hereditary angioneurotic edema plasma (Fig. 
3).  However, ellagic  acid-activated  Hageman  factor  prepared  from  plasma 
deficient  in PTA generated a larger  amount of ALTEE-hydrolytic activity in V.  H.  DONALDSON  417 
hereditary angioneurotic edema plasma more rapidly than did PTA-deficient 
Hageman factor not treated with ellagic acid. Activated Hageman factor pre- 
pared from normal plasma  and hereditary angioneurotic edema plasma  also 
readily induced ALTEE-esterolytic activity in hereditary angioneurotic edema 
plasma.  Apparently  activated  Hageman  factor  was  required  to  hasten  the 
formation of ALTEE-esterase activity. 
Since activated Hageman factor is a potent clot-promoting agent, the ability 
of these preparations to shorten the clotting time of Hageman factor-deficient 
plasma was measured to define any correlation between their capacity to induce 
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FI6. 3. Crude Hageman factor prepared from PTA-deficient  plasma and from Hageman 
factor-deficient  plasma was mixed with 10  -4 M  eUagic acid, or with buffer, and 0.2 ml of each 
of these mixtures, then incubated with 0.5 ml of hereditary angioneurotic edema plasma at 
37°C for 1 hr in silicone-coated  vessels. The rates of ALTEE hydrolysis  by 0.5 ml samples of 
each mixture were compared during continuous automatic titration to pH 7.4 at 37°C. Open 
circles, plasma treated with ellagie acid-activated PTA-deficient Hageman factor. Closed 
circles, plasma treated with the  PTA-deficient Hageman factor  (unactivated). Triangles, 
plasma treated with ellag[c acid-activated "Hageman-deficient"  Hageman factor. 
esterase activity and to promote clotting.  The Hageman-deficient Hageman 
factor preparation failed to shorten the clotting time of this plasma in the pres- 
ence of calcium, kaolin, and phospholipid, a mixture known to activate Hage- 
man factor and to permit the subsequent events leading to thrombin generation 
to occur (19, 20)  (Table I). The Hageman factor from PTA-deficient plasma 
significantly  shortened  the  clotting  time  of  an  otherwise  identical  mixture 
(Table I). When preparations of Hageman factor were tested for their ability 
to shorten the clotting time of Hageman factor-deficient plasma in the presence 
of only cephalin and calcium, Hageman factor from normal plasma and PTA- 
deficient plasma significantly shortened the clotting time of the mixture (Table 
I). Again, preparations of Hageman factor from plasma deficient in this factor 
were ineffective. Since this assay measures the clot-promoting activity of any 418  ACTIVATION OF  Ctl  ESTERASE 
Hageman factor already activated in the preparations tested (13), these experi- 
ments indicate that some of the Hageman factor had become activated during 
its preparation.  From 5-10%  of  the Hageman  factor  in more purified prep- 
arations was  activated during fracfionation  (14).  All of the tlageman factor 
preparations which had clot-promoting activity could increase the rate of gen- 
eration of ALTEE-esterase activity to some degree in hereditary angioneurotic 
TABLE I 
Clot-Promoting Activity of Partially Purified Preparations of Itageman Factor 
Sample 
Hageman  factor  from  Hageman  factor-deficient 
plasma 
Undiluted 
Hageman factor from PTA-deficient plasma 
Undiluted 
1/10 dilution 
1/40 dilution 
Buffer control 
Hageman factor from normal plasma 
Undiluted 
Buffer control 
Clotting time 
Unactivated and 
activated Hageman 
factor 
over 1740 
Already activated 
Hageman factor 
over 1700 
190  485 
210 
350 
2880 
--  466 
1740  over 3000 
To measure the total Hageman factor activity in a partially purified fraction of this sub- 
stance, 0.1 ml of this preparation was mixed with 0.1 ml of a  Gliddex-kaolin  mixture and 
0.1 ml of plasma deficient in Hageman factor in Pyrex test tubes. Mter incubation at 37°C 
for 8 rain to allow activation of the unactivated Hageman factor and its interaction with 
the plasma thromboplastin antecedent in the plasma, 0.1 ml of 0.025 ~ calcium chloride was 
added, mixed, and the time required for visible fibrin formation measured. To measure  the 
already activated Hageman factor, 0.1 ml of the Hageman factor preparation was incubated 
with 0.1 ml of a solution of 0.06 nag of cephalin/ml of barbital-saline buffer, pH 7.4, and 0.1 
ml of Hageman factor-deficient plasma in silicone-coated Pyrex test tubes. After incubation 
for 8 rain at 37°C, to allow the activated Hageman factor to interact with the plasma, 0.1 
ml of the calcium chloride was added, mixed, and the time needed for clotting measured. 
edema plasma even without treatment with ellagic acid. Thus,  the capacity of 
the Hageman factor preparations to enhance the clotting of plasma deficient in 
Hageman factor, bore a  relationship to their ability to  increase the generation 
of ALTEE-esterase activity in hereditary angioneurotic edema  plasma.  Acti- 
vated  partially  purified  Hageman  factor  did  not  induce  ALTEE-esterase 
activity in normal plasma. 
Identity of the Esterase Activity Generated with C'1 Esterase.--Although  it has V.  H.  DONALDSON  419 
been  shown that the digestion of ALTEE by plasma under the  conditions  of 
pH and ionic strength of the assays employed in these experiments apparently 
reflects the action of Ctl esterase (1, 3), further confirmation was sought. When 
two units of purified human serum inhibitor of Ctl esterase were  added to a 
mixture of  activated Hageman factor  and  hereditary angioneurotic  edema 
plasma which had already begun to hydrolyze ALTEE, the rate of esterolysis 
dropped from 0.9/zmole/min to 0 within 1 rain. No further esterolysis occurred 
in the following 10 min. The observed inhibition supports the likelihood that the 
esterase measured was C'I esterase. 
Since C'I esterase in solution can inactivate the fourth (C'4)  component of 
complement  (18), hereditary angioneurotic  edema  plasma  which  had  been 
incubated with activated Hageman factor was tested for its ability to inactivate 
the hemolytic C'4 in serum depleted of C'I and CJ2 by heating to 56°C for 30 
min. Activated Hageman factor, hereditary angioneurotic edema plasma, buffer, 
and ALTEE were mixed and observed in the pH-stat for any drop in pH. At 
intervals noted (Table  II), 0.2 ml samples were removed  from the titration 
vessel, mixed with 0.4 ml of heated serum, incubated at 0°C for 30 min, and the 
residual C'4 was then measured in a hemolytic assay. 
Activated  Hageman  factor  derived  from  normal  plasma,  PTA-deficient 
plasma and Hageman factor-deficient plasma did not directly inactivate CP4. 
However, during incubation of either normal or PTA-deficient activated Hage- 
man factor with hereditary angioneurotic edema plasma, CJ4-inactivating prop- 
erties  appeared  immediately (Table  II).  In the absence  of added Hageman 
factor, hereditary angioneurotic edema plasma less readily inactivated C'4 after 
its incubation with eUagic acid or with buffer. Ellagic acid-activated Hageman 
factor from Hageman factor-deficient plasma increased the rate of formation of 
C'4-inactivating property somewhat, but slightly more rapidly than did ellagic 
acid  alone. None of the activated Hageman factor preparations induced the 
normal plasma to destroy C4. The normal plasma contained a normal amount 
of inhibitor of C~I esterase. 
C'4 is a natural substrate for C'1 esterase, and its inactivation is a much more 
sensitive way of measuring small amounts of C~I esterase than is the digestion 
of ALTEE. The fact that the generation of ALTEE-esterase activity in heredi- 
tary angioneurotic  edema plasma treated with activated Hageman factor was 
closely associated with the formation of a property which inactivates C"4 sup- 
ports  the  liklihood  that the ALTEE-esterolytic activity was  identical with 
that of C'I esterase. 
Since these studies indicated a role for Hageman factor in the activation of 
C'I esterase in plasma from persons with hereditary angioneurotic edema, it was 
possible that activated Hageman factor was a necessary prerequisite. To explore 
this possibility,  a crude preparation of C'I esterase derived from serum of an 
individual with Hageman trait was  tested for its C'I  esterase-like  activity. 
After  activation,  this  Hageman  factor--deficient  C'1  esterase  hydrolyzed 420  ACTIVATION OF Cq  ESTERASE 
ALTEE  and inactivated C'4 in solution in a  manner quantitatively parallel to 
the action of C'I esterase derived from normal serum. 
The Effect of Some Inhibitors upon the Generation of C~1 Esterase in Hereditary 
Angioneurotic Edema Plasma by Activated Hageman Factor.--The activation of 
C'I  in  mixtures  of  activated Hageman  factor  and  hereditary angioneurotic 
edema  plasma  obtained  during  remissions  was  impaired  by  some  inhibitors 
which block some other plasma enzymes, but not C'I esterase. Soy bean trypsin 
TABLE II 
Inactivation of Ct  4 in Solution by Mixtures of Hageman Factor and Hereditary Angioneurotic 
Edema (HAE) Plasma 
Per cent of C'4 inactivated  by: 
Activated Hageman-  Activated  Hageman  Time  Activated  Hageman  deficient "Hageman  Ellagic  acid  Buffer  -}- tIAE  factor  from normal 
factor -t- HAE  factor" -t- HAE  -}- HAE plasma  plasma  plasma -I- buffer 
plasma  plasma  (no IIAE plasma) 
M/n 
0 
10 
15 
25 
46 
66 
76 
86 
100  25 
81 
88 
over 90 
0 
50 
75 
94 
0 
81 
over 90 
Plasma from an individual with hereditary angioneurotic  edema in remission was incu- 
bated either with ellagic acid-activated Hageman factor from PTA-deficient  plasma, ellagic 
acid-activated Hageman factor from Hageman-deficient plasma, 10  -4 ~ ellagic acid, or buffer 
for 60 min at 37°C in silicone-coated Lusteroid test tubes. Then, 0.5 ml of the incubation 
mixture to be tested was added to 1.875 ml of sodium phosphate buffer, pit 7.4, in a siliconed 
constant temperature titration vessel and, after warming the mixture to 37°C for 10 rain, 
0.125 ml of 1.6 ~ ALTEE was added. At the times noted, 0.2 ml samples were removed from 
the continuous-titration mixture and tested for their capacity to inactivate C'4 in heated 
serum. Aliquots of the same sample of hereditary angioneurotic edema plasma were used in 
each mixture in this experiment. 
inhibitor can inhibit plasmin (21, 22), plasma kallikrein (23), and one or more 
clot-promoting  substances  effective  in  the  conversion  of  prothrombin  to 
thrombin (24, 25). It does not inhibit the action of C'1 esterase upon ALTEE 
(26). When this inhibitor was added to hereditary angioneurotic edema plasma 
prior  to  its  incubation  with  activated  Hageman  factor,  the  generation  of 
ALTEE-esterase activity in the mixture was inhibited (Fig. 4). 
Heparin did not inhibit the hydrolysis of ALTEE by hereditary angioneurotic 
edema plasma during continuous titration. It did not change the rate of hydrol- 
ysis of this ester during such a titration beyond the temporary effect of dilution, V.  H.  DONALDSON  421 
which was also noted if buffer were added to the titration mixture once esterol- 
ysis had begun. However, when heparin in identical concentrations (125 USP 
units/ml) was added to hereditary angioneurotic edema plasma before the acti- 
vated Hageman factor, it did block the generation of this esterolytic property 
(Fig. 4). 
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MINUTES  INCUBATION  WITH  ALTEE 
FIG. 4.  In this experiment, 0.18  ml of e]]agic acid-activated  crude Hageman factor was 
mixed with 0.02 ml of buffer (open circles), 0.02 ml of soy bean trypsin inhibitor, 10 mg/ml 
(closed circles),  0.02 ml of heparin, 1000 U/ml (triangles) or 0.02 ml of Trasylol,  5000 U/ml (X). 
Then, 0.5 ml of hereditary angioneurotic  edema plasma was added to each, mixed well, and 
these mixtures incubated at 37°C for 40 rain before being tested for ALTEE esterase activity 
using the method of continuous titration described. 
Trasylol in  high  concentrations  (625  units/ml)  delayed the  generation  of 
ALTEE-esterase activity in mixtures of hereditary angioneurotic edema plasma 
and activated Hageman factor, but to a smaller degree than did either heparin 
or soy bean trypsin inhibitor. Once esterolysis began,  the mixture containing 
Trasylol hydrolyzed even more ALTEE within the ensuing 20 rain than did a 
control mixture containing buffer instead of Trasylol (Fig. 4). Trasylol did not 
inhibit the esterolytic activity of preparations of activated C'I esterase.  1 422  ACTIVATION OF  ctl  ESTERASE 
Epsilon aminocaproic acid can inhibit several proteolytic ezymes (27),  but 
in a  concentration of 0.1 ~  does not, to our knowledge, delay the clotting or 
normal plasma or inhibit esterolysis by C'1 esterase3 It can, however, impair 
the activation of Crl on sensitized erythrocytes (28). The effect of 0.1 M epsilon 
aminocaproic acid on the generation of C'1 esterase in mixtures of hereditary 
angioneurotic edema plasma  and  activated  ttageman  factor  was  quite  un- 
predictable, as noted in other experiments testing the effect of urokinase upon 
the activation of Crl in these plasma samples.  ~ 
DISCUSSION 
The ALTEE-esterase activity which can be generated in plasma obtained 
from persons with hereditary angioneurotic edema can be identified with C'I 
esterase  because  its  appearance  was  associated  with  the  development  of  a 
property which inactivated C'4 (18, 29), and because a preparation of inhibitor 
of C'I  esterase representing at least a  2000-fold  purification with respect  to 
serum,  inhibited  this  esterolytic activity  (30).  In  the  present  experiments, 
highly purified preparations of activated Hageman factor enhanced the gen- 
eration of C'I esterase activity in hereditary angioneurotic edema plasma. The 
rate of generation and the amount of C'I esterase formed were proportional to 
the amount of purified activated Hageman factor used (Fig. 2). If derived from 
plasma deficient in Hageman factor, a fraction normally rich in this activity 
failed to develop clot-promoting activity when activated, and similarly failed 
to induce C'I esterase activity in hereditary angioneurotic edema plasma (Fig. 
3).  Hageman factor appeared  to be necessary for both. The initial bursts of 
esterolytic activity were unexplained (Fig. 1-4). 
While activated Hageman factor did not induce formation of free C'I esterase 
in normal plasma, it was possible that any C'I esterase formed was obscured by 
the normal inhibitor, but might have been detected indirectly by measuring 
consumption of normal inhibition in the plasma after its incubation with acti- 
vated Hageman factor. However, it was not possible to show conclusively a sig- 
nificant decrease in normal plasma inhibition after prolonged incubation of the 
mixture, perhaps reflecting the relative insensitivity of the method for measur- 
ing inhibition. 
Some substances which do not themselves inhibit Cq esterase, impaired the 
effect of activated Hageman factor upon the activation of C'I  in hereditary 
angioneurotic edema plasma.  Soy bean  trypsin inhibitor does not block the 
esterolytic activity of C'I esterase (26), but does inhibit some other hydrolytic 
enzymes which may appear  in  plasma  (21-25).  Heparin  also fails to  block 
esterolysis by C'I esterase, but inhibits some of the plasma enzymes participat- 
ing in coagulation (31).  Both of these substances markedly inhibited the gen- 
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eration of C'l  esterase in hereditary  angioneurotic  edema plasma during  its 
incubation  with  activated Hageman  factor.  Therefore, C'1  must have  been 
activated after some intermediate steps initiated by activated Hageman factor 
and susceptible to inhibition by soy bean trypsin inhibitor and heparin. 
Other  enzymes active in coagulation might  have been involved.  Soy bean 
trypsin inhibitor in a concentration of 500 ug/ml did not prevent the interaction 
of activated Hageman factor with plasma  thromboplastin  antecedent in the 
generation  of clot-promoting  activity in  the  studies of Ratnoff, Davie,  and 
Mallett (10). In the present experiments, 250 ug of soy bean trypsin inhibitor 
per ml of titration mixture blocked the ability of activated Hageman factor to 
generate C'1 esterase. It is therefore unlikely that the activated Hageman factor 
affected C'I directly after interacting with plasma thromboplastin antecedent 
in  hereditary  angioneurotic  edema  plasma,  for  inhibition  should  not  have 
occurred. A later enzymatic reaction effective in coagulation is very sensitive 
to soy bean trypsin inhibitor (24). Heparin can block the next step in coagula- 
tion in which there is an interaction of plasma thromboplastin antecedent and 
Christmas  factor,  initiated  by activated  Hageman  factor  (32).  Thus,  later 
acting coagulation enzymes might participate in the formation of C'1 esterase in 
hereditary angioneurotic edema plasma treated with activated Hageman factor. 
The activation of C'1 esterase in the presence of activated Hageman factor 
results more likely from some of the enzymatic events which  can lead to the 
formation  of vasoactive polypeptides, called  kinins,  as  illustrated  in  Fig.  5. 
Margolis (33) and Ratnoff and Miles (34) found that activated Hageman factor 
was required for the generation of permeability factor activity in normal plasma 
diluted and shaken with glass. The development of the permeability property 
could be inhibited by soy bean trypsin inhibitor,  and  heparin,  and  was not 
dependent  upon  the  interaction  of  activated  Hageman  factor  with  plasma 
thromboplastin  antecedent  or  other  later  acting  coagulation  factors  (34). 
Neither  heparin  nor  soy bean  trypsin  inhibitor  impaired  this  permeability 
factor activity once it was formed.  These inhibitors behaved in like manner 
toward  the  activation  of  C'1  by activated  Hageman  factor  in  the  present 
experiments. 
It has been proposed that  a  globulin  permeability factor of plasma which 
requires activated Hageman factor for its formation does not directly release 
kinins,  but  can  activate  a  plasma  kinin-forming  enzyme,  called  kallikrein 
(35, 36). The studies of Margolis (37),  as well as those of Armstrong and her 
associates (38), Spector (39), Webster and Ratnoff (40), and Ratnoff and Miles 
(34) provide evidence suggesting  that Hageman factor, once activated, may in 
some  way induce  the  formation  of  kinins  which cause  increased  vascular 
permeability, pain,  vasodilitation,  and  can induce the isolated rat uterus to 
contract.  The mechanism  of kinin formation seems not to involve the other 
clot-promoting  enzymes in  plasma,  but  rather,  the  interaction  of activated ~,. 
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Hageman factor with other plasma enzymes leading eventually to kinin release 
(Fig.  5). In this regard, Landerman and his associates (41) and Burdon et al. 
(42) have reported that a kallikrein  system may participate in the formation of 
plasma  kinin  in  hereditary  angioneurotic  edema  serum.  Landerman  et  al. 
reported a deficiency  of the normal serum inhibition directed against a prep- 
aration of plasma kaUikrein and/or globulin permeability factor in hereditary 
angioneurotic edema plasma (41). Subsequently, Kagan has found that a par- 
tially purified preparation of inhibitor of C'1 esterase can inhibit preparations 
of plasma permeability globulin and of kallikrein  (43). Perhaps, then, activated 
Hageman factor induces the formation of an active globulin permeability factor 
(34), which then directs events releasing kinin and culminating in the activation 
of C'I esterase in hereditary angioneurotic edema plasma. We have found that 
a  kinin-like  substance forms readily in the blood of persons with hereditary 
angioneurotic edema (44) which can increase vascular permeability in the skins 
of experimental animals  and of persons with hereditary angioneurotic edema 
(45). This effect is not mediated through the release of histamine but appears to 
be due to the action of a polypeptide (44). It is therefore logical to postulate 
that a kinin-forming  system of plasma may be involved in the mechanism of 
activation of C'I by activated Hageman factor (Fig. 5). 
Trasylol can inhibit some kallikreins  (46) and plasmin,  a fibrinolytic enzyme 
of blood, but does not block the generation of clot-promoting activity in normal 
plasma in concentrations of I00 units/ml? This substance was less effective in 
blocking the generation of C'I esterase than either heparin or soy bean trypsin 
inhibitor. The explanation of the increased  amount of esterolysis which even- 
tually developed in incubation mixtures containing  Trasylol is not apparent. 
Plasma enzymes which participate in fibrinolysis might also direct a series of 
reactions initiated by activated Hageman factor and ultimately leading  to the 
activation of C'I esterase in plasma from persons with hereditary angioneurotic 
edema  (Fig.  5). 1 Niewiarowski and  Wartelle  (47),  and  Iatridis and  Ferguson 
(48) have provided some experimental support for the concept that the initiation 
of clot-promoting activity by the activation of the Hageman factor in pIasma 
can accelerate the rate of formation of fibrinolytic activity. It has been repeat- 
edly observed that plasmin,  a fibrinolytic enzyme of blood, can activate the 
first component of complement (26, 49, and footnote 1). Therefore, activated 
Hageman factor might  enhance the fibrinolytic activity of hereditary angio- 
neurotic edema plasma, and this might in turn influence the rate of generation 
of C'I esterase (Fig. 5). 
These  experiments  in  no  way demonstrate  a  role  for activated Hageman 
factor in  the genesis  of the sporadic bouts of edema to which  persons with 
hereditary angioneurotic edema are subject. We know of no individual with an 
inherited deficiency of Hageman factor who also lacks serum inhibition of C'I 
esterase. It would be interesting to know if such a doubly blighted person would 426  ACTIVATION OF  Ctl  ESTEltASE 
be subject to bouts of hereditary angioneurotic edema, as the absence of serum 
inhibition of C'I esterase would lead one to predict.  The fact that crude C'I 
esterase,  prepared  from  serum  of  a  person  markedly  deficient  in  Hageman 
factor,  hydrolyzed ALTEE  and  inactivated  C'4,  just  as  C'I  esterase  from 
normal serum did, indicates that there is no absolute requirement for activated 
Hageman factor in the in vitro activation of crude C'I esterase. 
SUMMARY 
The generation of C'I esterase  activity in  siliconed plasma  obtained  from 
individuals with hereditary angioneurotic edema in  remission  tends  to occur 
spontaneously, but can be hastened during its incubation with preparations of 
activated Hageman factor. This effect of activated Hageman factor could not 
be shown during its incubation with normal siliconed plasma,  nor could con- 
sumption of normal serum inhibition of C'I esterase be clearly shown. 
Soy bean trypsin inhibitor and heparin could impair this enhanced generation 
of C'I esterase  but  neither  inhibits  the  esterolytic function  of  C'I  esterase 
once formed. Trasylol was less effective in blocking this effect of activated Hage- 
man factor. 
While  the mechanism of the  effect of activated Hageman factor upon C'I 
activation remains obscure, it is apparent  that some intermediate  steps,  pos- 
sibly involving a kinin-forming system of plasma, may play a role. 
Dr. Fred S. Rosen of The Children's Hospital Medical Center, Boston, Mass., provided 
some of the plasma samples from persons with hereditary angioneurotic edema, and  Dr. 
Rudolf Goesswald of FBA Medical Research Division of Metachem, Inc., New York, pro- 
vided the samples of Trasylol (Preparation A 128). Technical assistance was provided by P. 
Kent Taylor, and the secretarial assistance of Joyce Davidson permitted completion of thc 
manuscript. 
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